Molecular Quality Control MarketSize and Trends

Molecular quality control mainly used for monitoring the performance of in vitro nucleic acid testing procedures for viral load assays, healthcare-associated infections (HAIs) including bloodstream infections, urinary tract infections, pneumonia, and other infections related to sexually transmitted diseases. Main focus of molecular quality control is to test molecular diagnostic products, identify defects and report them to management authorities.

Molecular Quality Control Market Drivers

Expansion of business by key players is expected to boost the molecular quality control market growth. For instance, in July 2016, Bio-Rad Laboratories, Inc. announced its expansion into the molecular diagnostic testing market with the launch of its new quality control system Amplichek Quality Control. This quality control is used for molecular diagnostic testing of infectious diseases.

Furthermore, in April 2019, Bruker announced the expansion for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines. These products will be used for microbial identification, infection control, and molecular diagnostics of infectious diseases.

Moreover, increasing partnership activities are expected to drive the molecular quality control market growth. For instance, in February 2018, Randox Laboratories announced its strategic partnership with Qnostics to enhance the market potential of its Qnostics products.

Molecular Quality Control Market Restraints

Inaccurate genetic tests are expected to hinder growth of the molecular quality control market. For instance, in August 2017, Invitae Corporation identified a quality control issue with a hereditary cancer test, which provided false, negative results. This hereditary cancer test is carried out on those patient who have a rare genetic variant in the MSH2 gene which is associated with the Lynch syndrome.

On the basis of region, the global molecular quality control market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold a dominant position in the global molecular quality control market, owing to increasing launches of new control panels by key players. For instance, in December 2018, Microbiologics, Inc. launched two new panels, Group A Streptococcus (GAS) and respiratory molecular assays, for quality control processes. These two panels include convenient features such as multiplexed pellets, swabs that mimic patient sample processing, and room temperature storage.

Furthermore, Asia Pacific is also projected to witness significant growth in the global molecular quality control market, owing to increasing partnership activities by key players. In June 2016, Thermo Fisher Scientific Inc., announced its partnership with West China Hospital of Sichuan University to enhance quality of pathological research and diagnosis and to accelerate development of precise pathological diagnosis.